Global heritage Leverage ONO Pharma’s long-standing R&D focus and history of first-in-class therapies to position advanced collaboration opportunities in oncology, immunology, neurology, and specialty medicine with US-based teams.

US subsidiary Target the US market potential by offering tailored support for clinical development, regulatory navigation, and early access programs aligned with ONO’s growing pipeline and potential expansion plans.

Phase progression Capitalize on the recent Phase 2 to Phase 3 advancement signals (such as ONO-2808 in MSA) to propose co-development, research collaborations, or co-funding opportunities with US CROs, biotech partners, and universities.

Health & productivity Align value propositions with ONO’s recognized Health & Productivity Management initiatives to present partnerships that enhance workforce well-being, patient access programs, and ESG-aligned sponsorships.

Strategic alliances Propose strategic collaborations with Sinopia Biosciences and other potential partners to accelerate target discovery and rare metabolic disorder programs, offering translational research, data sharing, and joint venture options.